Library
Agency issuances
16,884 issuances · 1941–2026
67 issuances from the 2010s
Newest first
- FDA Circular No. 2014-001 TRAINING COURSES AND SCHEDULE OF FEES FOR THE TRAININGS OFFERED BY THE FDA ACADEMY – POLICY PLANNING OFFICE FOR CALENDAR YEAR 2014
- FDA Circular No. 2013-029 FILING OF APPLICATIONS FOR LICENSING OF TOY ESTABLISHMENTS AND REGISTRATION OF TOY PRODUCTS TO THE CENTER FOR COSMETIC REGULATION AND RESEARCH THROUGH THE FDA-PAIR UNIT
- FDA Circular No. 2013-027 WAIVER OF INITIAL AND RENEWAL APPLICATION FEES FOR LICENSE TO OPERATE AS DRUG OUTLETS OR PHARMACIES IN CALAMITY AREAS IN LEYTE AND EASTERN SAMAR UNTIL DECEMBER 31, 2014, AND FOR OTHER PURPOSES
- FDA Circular No. 2013-028 SUSPENSION OF MANUFACTURE, IMPORTATION, DISTRIBUTION, AND/OR MARKETING OF KETOCONAZOLE ORAL PRODUCTS
- FDA Circular No. 2013-026 ADOPTION OF THE ICH HARMONISED TRIPARTITE GUIDELINE, QUALITY OF BIOTECHNOLOGICAL PRODUCTS: STABILITY TESTING OF BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS Q5C
- FDA Circular No. 2013-025 AMENDMENT OF THE CERTIFICATE/S OF PRODUCT REGISTRATION (CPRS) OF DRUG PRODUCTS
- FDA Circular No. 2013-024 ADOPTION AND IMPLEMENTATION OF “THE MEXICO CITY PRINCIPLES FOR VOLUNTARY CODES OF BUSINESS ETHICS IN THE BIOPHARMACEUTICAL SECTOR”
- FDA Circular No. 2013-023 CLARIFICATION ON THE PROVISIONS OF ADMINISTRATIVE ORDER NO. 2013-0022, ON THE GUIDELINES FOR CURRENT GOOD MANUFACTURING PRACTICE (cGMP) CLEARANCE AND INSPECTION OF FOREIGN DRUG MANUFACTURERS
- FDA Circular No. 2013-022 GUIDELINES ON HANDLING CONSUMER COMPLAINTS
- FDA Circular No. 2013-021 COMPARATOR DRUGS FOR SELECTED PHARMACEUTICAL PRODUCTS CONTAINING BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS) CLASS 4 DRUG MOLECULES
- FDA Circular No. 2013-020 REITERATION OF REGISTRATION OF HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS
- FDA Circular No. 2013-019 ORGANIZATION OF THE ASEAN COMMON TECHNICAL DOSSIER (ACTD) FOR THE REGISTRATION OF PHARMACEUTICAL PRODUCTS FOR HUMAN USE
- FDA Circular No. 2013-018 ADOPTION OF THE INTERNATIONAL CONFERENCE ON HARMONIZATION (ICH) SAFETY AND EFFICACY GUIDELINES
- FDA Circular No. 2012-015 GUIDELINES ON VOLUNTARY DECLARATION OF THE FRONT PACK LABELING (ENERGY OR CALORIE CONTENT) ON THE LABELS OF PROCESSED FOOD PRODUCTS
- FDA Circular No. 2012-013 REITERATION ON THE POLICY ON CONFIDENTIALITY OF INFORMATION
- FDA Circular No. 2012-012 GUIDELINES FOR HANDLING RAPID ALERTS ARISING FROM QUALITY DEFECTS
- FDA Circular No. 2012-011 AUTHORITY OF FDA INSPECTORS
- FDA Circular No. 2012-010 GUIDANCE ON CONFLICT OF INTEREST
- FDA Circular No. 2012-009 DECLARING THE BELOW IDENTIFIED ADDITIONAL COSMETIC PRODUCTS TO BE IMMINENTLY INJURIOUS, UNSAFE OR DANGEROUS AND AUTHORIZING THE FDA INSPECTORS TO SEIZE THE PRODUCTS LISTED THEREIN FROM PUBLIC SALE OR DISTRIBUTION
- FDA Circular No. 2012-014 DISPOSITION OF FLOOD-AFFECTED HEALTH PRODUCTS
- FDA Circular No. 2012-008 LICENSING AND REGISTRATION SEMINAR FOR FOOD ESTABLISHMENTS
- FDA Circular No. 2011-004 COMPUTATION OF SURCHARGE OR PENALTY IMPOSABLE IN CASE OF SUBMISSION OF RENEWAL OF APPLICATIONS COVERING LICENSE OF ESTABLISHMENTS AND REGISTRATION OF HEALTH PRODUCTS AFTER THEIR DATE OF EXPIRATION PURSUANT TO SECTION 3, PARAGRAPHS (A)(2) AND (B)(2) OF ARTICLE I OF BOOK II OF THE RA 9711 IMPLEMENTING RULES AND REGULATIONS, AND OTHER PURPOSES
- FDA Circular No. 2011-003-A REVISION TO THE SCHEDULE OF FEES LISTED IN FDA CIRCULAR NO. 2011-003 DATED 24 JUNE 2011 ON THE COLLECTION OF LEGAL RESEARCH FEE IMPOSED BY REPUBLIC ACT NO. 3870, AS AMENDED BY PD 200 AND FURTHER AMENDED BY PD 1856
- FDA Circular No. 2011-003 COLLECTION OF LEGAL RESEARCH FEE IMPOSED BY REPUBLIC ACT NO. 3870, AS AMENDED BY PD 200 AND FURTHER AMENDED BY PD 1856
- FDA Circular No. 2011-002 APPLICATION FOR REVISIONS/UPDATES IN THE PACKAGE INSERT, PATIENT LEAFLET INFORMATION, PRESCRIBING INFORMATION, CORE DATA SHEET AND BASIC SUCCINCT STATEMENT